Melanoma Clinical Trial

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Summary

This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation (phase 1) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001, and a dose expansion (phase 2) which characterized treatment of LAG525 in combination with PDR001 at the MTD or RP2D.

View Full Description

Full Description

This was a Phase 1/2, multi-center, open-label study comprising a Phase 1 dose escalation part followed by a Phase 2 dose expansion part.

During the Phase 1 dose escalation part patients with any advanced solid tumor received the study treatment until the MTD was reached or a lower RP2D was established. The study had the following 3 dose escalation parts: 1) Single-agent LAG525; 2) Single-agent LAG525 in Japanese patients; 3) Combination of LAG525 with PDR001.

Once the RP2D or MTD had been determined in the escalation parts, additional patients were to be enrolled in the Phase 2 expansion parts in order to assess the preliminary anti-tumor activity. Phase 2 expansion cohorts testing single-agent LAG525 were not opened for enrollment based on emerging data including but not limited to preliminary anti-tumor activity. Phase 2 expansion cohorts for the combination of LAG525 with PDR001 were opened and 5 tumor types were assessed: 1) Non-small cell lung cancer (NSCLC); 2) Melanoma; 3) Renal cell cancer (RCC); 4) Mesothelioma; 5) Triple negative breast cancer (TNBC). The efficacy and safety of the combination of LAG525 with PDR001 in these tumor types was assessed in both the PD-1/PD-L1 pre-treated and naïve settings.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Phase I part:

- Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST version 1.1, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists

Phase II part:

Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who have had disease progression following their last prior therapy and fit into one of the following groups:
Group 1: NSCLC
Group 2: Melanoma
Group 3: Renal cancer
Group 4: Mesothelioma
Group 5: TNBC
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1
Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy.

Exclusion Criteria:

History of severe hypersensitivity reactions to study treatment ingredients or other mAbs
Active, known or suspected autoimmune disease
Active infection requiring systemic antibiotic therapy
HIV infection. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Patients receiving chronic treatment with systemic steroid therapy, other than replacement-dose corticosteroids in the setting of adrenal insufficiency
Patients receiving systemic treatment with any immunosuppressive medication
Use of live vaccines against infectious disease within 4 weeks of initiation of study treatment
Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment.
Presence of symptomatic central nervous system (CNS) metastases or CNS metastases that require local CNS-directed therapy or increasing doses of corticosteroids within the prior 2 weeks
History of drug-induced pneumonitis or current pneumonitis.

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

490

Study ID:

NCT02460224

Recruitment Status:

Completed

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 23 Locations for this study

See Locations Near You

Columbia University Medical Center SC LAG X2101C
New York New York, 10032, United States
Memorial Sloan Kettering Cancer Center SC
New York New York, 10065, United States
Duke Clinical Research Institute SC
Durham North Carolina, 27704, United States
University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States
Cancer Therapy and Research Center UT Health Science Center CTRC 2
San Antonio Texas, 78229, United States
Huntsman Cancer Institute Huntsman Cancer Institute
Salt Lake City Utah, 84112, United States
Novartis Investigative Site
Westmead New South Wales, 2145, Australia
Novartis Investigative Site
Heidelberg Victoria, 3084, Australia
Novartis Investigative Site
Leuven , 3000, Belgium
Novartis Investigative Site
Edmonton Alberta, T6G 1, Canada
Novartis Investigative Site
Toronto Ontario, M5G 2, Canada
Novartis Investigative Site
Lyon Cedex , 69373, France
Novartis Investigative Site
Saint-Herblain Cédex , 44805, France
Novartis Investigative Site
Heidelberg , 69120, Germany
Novartis Investigative Site
Wuerzburg , 97080, Germany
Novartis Investigative Site
Hong Kong , , Hong Kong
Novartis Investigative Site
Milano MI, 20133, Italy
Novartis Investigative Site
Modena MO, 41124, Italy
Novartis Investigative Site
Fukuoka-city Fukuoka, 811-1, Japan
Novartis Investigative Site
Singapore , 11922, Singapore
Novartis Investigative Site
Singapore , 16961, Singapore
Novartis Investigative Site
Barcelona Catalunya, 08035, Spain
Novartis Investigative Site
Madrid , 28009, Spain
Novartis Investigative Site
Taipei , 10002, Taiwan

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 1

Estimated Enrollment:

490

Study ID:

NCT02460224

Recruitment Status:

Completed

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider